U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H15NO2.C7H6O3
Molecular Weight 307.3416
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACECLIDINE SALICYLATE

SMILES

OC(=O)C1=C(O)C=CC=C1.CC(=O)OC2CN3CCC2CC3

InChI

InChIKey=RGVBDFIRGIDMNP-UHFFFAOYSA-N
InChI=1S/C9H15NO2.C7H6O3/c1-7(11)12-9-6-10-4-2-8(9)3-5-10;8-6-4-2-1-3-5(6)7(9)10/h8-9H,2-6H2,1H3;1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C9H15NO2
Molecular Weight 169.2209
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C7H6O3
Molecular Weight 138.1207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594

Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mouse; rats. Human data not available

Originator

Curator's Comment: Aceclidine was first prepared in 1960

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glaunorm

Approved Use

Glaucoma, in its different clinical forms

Launch Date

1969
PubMed

PubMed

TitleDatePubMed
Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial.
2005 Sep
Aceclidine and pilocarpine interact differently with muscarinic receptor in isolated rabbit iris muscle.
2006 Feb 28
Role of cholinergic and cytokine regulation of T cell function in stimulation and inhibition of immune reactions in intoxication by organophosphorus compounds in different doses.
2009 Sep
Patents

Sample Use Guides

Instill 2 drops of Glaunorm (2% aceclidine hydrochloride solution) into the conjunctival sac every 8 hours following the doctor's prescription
Route of Administration: Topical
Human eyes were dissected and perfused. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 1 nM to 10 mM of aceclidine, were added to the perfusion medium. Outflow facility increased from baseline facility in eyes treated with aceclidine at lower concentrations (1 nM to 1 uM) but remained unchanged at higher concentrations.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:26:44 GMT 2023
Edited
by admin
on Fri Dec 15 15:26:44 GMT 2023
Record UNII
MCC2GG434J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACECLIDINE SALICYLATE
Common Name English
2-HYDROXYBENZOIC ACID - 1-AZABICYCLO(2.2.2)OCT-3-YL ACETATE (1:1)
Systematic Name English
SALICYLIC ACID, COMPD. WITH 3-QUINUCLIDINOL ACETATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47796
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C96882
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID90987715
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
PRIMARY
FDA UNII
MCC2GG434J
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
PRIMARY
CAS
6821-59-6
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
PRIMARY
PUBCHEM
23260
Created by admin on Fri Dec 15 15:26:44 GMT 2023 , Edited by admin on Fri Dec 15 15:26:44 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY